Business Context and Reporting Period
This Form 8-K was filed by AmerisourceBergen Corporation (now Cencora, Inc.) on December 4, 2017. The report details the completion of a debt offering and the entry into material definitive agreements regarding new senior notes.
Key Financial Metrics and Debt Issuance
The Company completed the sale of $1.25 billion in aggregate principal amount of senior notes, consisting of two tranches:
- 2027 Notes: $750 million aggregate principal amount, bearing interest at 3.45% per year, maturing December 15, 2027.
- 2047 Notes: $500 million aggregate principal amount, bearing interest at 4.30% per year, maturing December 15, 2047.
Interest on both tranches is payable semiannually in arrears beginning June 15, 2018. The notes are unsecured and unsubordinated obligations, ranking equally with existing unsecured indebtedness but structurally subordinated to subsidiary liabilities.
Material Changes and Covenants
The issuance creates new direct financial obligations and introduces specific covenants and redemption terms:
- Redemption Rights: The Company may redeem the 2027 Notes prior to September 15, 2027, at a "make-whole" price, and the 2047 Notes prior to June 15, 2047, at a "make-whole" price. Post-these dates, redemption is at 100% of principal plus accrued interest.
- Change of Control: In the event of a change of control, the Company must offer to purchase the notes at 101% of principal plus accrued interest.
- H.D. Smith Acquisition Contingency: The Company is required to redeem the 2047 Notes in whole at 101% of principal if the acquisition of H.D. Smith is not completed by May 20, 2018, or if the acquisition agreement is terminated prior to that date.
- Covenants: The indentures limit the ability to create liens, enter into sale and leaseback transactions, and merge or consolidate with other entities.
Guidance, Risks, and Forward-Looking Statements
The filing includes extensive forward-looking statements regarding the Company's expectations and risks. Key risk factors identified include:
- Regulatory and Legal: Risks related to opioid abuse, controlled substance diversion, government enforcement, and pending litigation (including qui tam litigation).
- Market Dynamics: Unfavorable trends in pharmaceutical pricing, competition, and reimbursement rate declines.
- Strategic Transactions: Uncertainties regarding the timing and completion of the H.D. Smith acquisition, integration challenges, and the potential failure to realize anticipated synergies.
- Operational: Risks associated with data privacy, information system failures, and the relationship with Walgreens Boots Alliance.
The filing does not provide specific revenue, profit, or cash flow figures for the reporting period, as it focuses solely on the debt issuance event.
Investor Verification Checklist
- Verify the final closing date and net proceeds received from the $1.25 billion note offering.
- Confirm the status of the H.D. Smith acquisition and whether the May 20, 2018, deadline for mandatory redemption of the 2047 Notes was met.
- Review the full text of the Seventh and Eighth Supplemental Indentures (Exhibits 4.1 and 4.2) for detailed covenant restrictions.
- Assess the impact of the new debt service obligations on the Company's liquidity and leverage ratios.
- Monitor updates on the legal proceedings mentioned in the risk factors, particularly those involving controlled substances and government enforcement.